To clarify the association of Chlamydia pneumoniae DNA in peripheral blood mononuclear cells (PBMCs) with acute coronary syndrome (ACS) and stable coronary artery disease (CAD) in Japanese adults, touchdownnested polymerase chain reaction was used to detect the presence of C. pneumoniae DNA. The prevalence of C. pneumoniae DNA in PBMCs was similar in a comparison of 88 patients (52.3%) with ACS, 164 patients (50.0%) with stable CAD, and 88 control subjects (50.0%). Temporal changes in the prevalence of C. pneumoniae DNA in PBMCs were also assessed every 3 months during a 1-year period ( ). The prevalence was n p 59 significantly higher in the first 3-month period (January through March) than in any of the other 3-month periods. In conclusion, the prevalence of C. pneumoniae DNA in PBMCs in patients with ACS or stable CAD was comparable to that in control populations. Furthermore, the presence of circulating C. pneumoniae was strongly associated with seasonal variability.
Chlamydia pneumoniae is an intracellular pathogen that is a common cause of respiratory tract infections worldwide. More than 60% of adults are infected with C. pneumoniae during their lifetime, and reinfections are common [1] . Since the report by Saikku et al. [2] describing elevated titers of IgG and IgA antibodies against C. pneumoniae in patients with recent myocardial infarction and chronic coronary artery disease (CAD), many studies have been performed to clarify the relationship between C. pneumoniae and atherosclerotic disease. C. pneumoniae has been detected in human atherosclerotic lesions by PCR [3, 4] , immunohistochemistry [3, 4] , electron microscopy [3] , and cell culture [5] [6] [7] , albeit in varying rates. Furthermore, viable pathogens have been recovered from atherosclerotic le-sions in coronary arteries [5] [6] [7] and carotid arteries [6] . Several in vitro studies [8] [9] [10] have demonstrated that C. pneumoniae infects endothelial cells, smooth muscle cells, and macrophages and reproduces within them. Laitinen et al. [11] demonstrated that intranasal infection with C. pneumoniae causes inflammatory atherosclerosis-like changes in the aorta of the rabbits. In a mouse model, Moazed et al. [12] demonstrated that C. pneumoniae infection disseminates systemically through the bloodstream after infection of alveolar macrophages. Several investigators have proposed that C. pneumoniae continues to live within macrophages and migrates along with them into the arterial wall. Other investigators have examined the relationship between C. pneumoniae DNA in PBMCs and CAD [13] [14] [15] [16] [17] [18] , carotid atherosclerosis [19, 20] , aortic aneurysms [21, 22] , and vascular surgery [23] .
Despite these data, it is still unclear whether the presence of C. pneumoniae DNA in PBMCs can be a useful indicator of CAD. Therefore, the goal of this study was to clarify the relationship between C. pneumoniae DNA in PBMCs and stable CAD or acute coronary syndrome (ACS) in Japanese adults. In addition, we examined the presence or absence of seasonal variability in the prevalence of C. pneumoniae DNA in PBMCs.
MATERIALS AND METHODS
Subjects in the first portion of the study. The prevalence of C. pneumoniae DNA in PBMCs was compared among 88 patients with ACS (59 with acute myocardial infarction and 29 with unstable angina pectoris), 164 with stable CAD, and 88 control subjects. Eligible patients with ACS or stable CAD who were admitted to our university or to 2 affiliated hospitals during the daytime between December 2001 and March 2002 and who met the following inclusion criteria were consecutively enrolled. Control subjects in the following patient groups were also enrolled in this study: outpatients at our university hospital with no evidence of CAD (e.g., no history of chest pain, no electrocardiographic abnormalities at rest, and a negative exercise stress test result;
), or patients who underwent n p 38 diagnostic coronary arteriography because of chest pain at our university or at 2 affiliated hospitals during the study period, without any subsequent evidence of significant coronary artery stenosis or coronary spasm ( ). Inclusion criteria for all n p 50 study populations were as follows: age, 140 years; no history of upper or lower respiratory tract infections or use of antibiotics within 4 weeks of the blood sampling; and no history of chronic respiratory tract disease. A diagnosis of acute myocardial infarction was made on the basis of the following criteria: typical chest pain lasting for 120 min, characteristic changes noted on the electrocardiograph, and a creatine kinase level of more than twice the upper limit of normal. Unstable angina pectoris was defined according to the Braunwald classification [24] . All patients with ACS or with stable CAD underwent coronary arteriography. Patients with stable CAD had 150% stenosis in у1 coronary artery or had undergone prior percutaneous coronary intervention in у1 vessel.
Subjects in the second portion of the study. Blood samples were obtained from subjects every 3 months to assess temporal changes in the prevalence of C. pneumoniae DNA in PBMCs. The subjects consisted of 60 persons who were recruited from the first portion of the study from January 2002 through March 2002 and who were able to see a physician (A.T.) at least once during each 3-month period for 1 year. The subject selection was completed before the results of the first portion of the study were obtained. One patient dropped out before the completion of the study. The other 59 subjects (27 patients with CAD and 32 control subjects) completed the study. All study protocols were in agreement with the guidelines of the ethics committee at our institution, and informed consent was obtained from each patient before the study.
PCR. PCR was performed according to the methodology described by Dowell et al. [25] . Whole venous blood samples (6 mL) from each patient were collected in EDTA-treated tubes. Blood samples were obtained at hospital admission from patients with ACS, patients with stable CAD, and control subjects without abnormal findings on coronary arteriographs. Blood samples for touchdown-nested PCR were processed in accordance with the method described by Condos et al. [26] . Blood samples were carefully layered over Separate-L (Muto Pure Chemicals) at a ratio of blood to Separate-L of 3:4. The buffy coat was obtained by centrifugation (700 g for 30 min, brake off) and then washed with phosphate-buffered saline (700 g for 10 min, brake on) in a total volume of 10 mL. Finally, the resulting PBMCs were eluted to 200 mL of PBS and transferred to a new tube for DNA extraction. DNA was extracted from PBMCs using a DNA minikit (QIAamp; Qiagen) in accordance with the manufacturer's instructions. DNA was eluted to a final volume of 200 mL and stored at Ϫ20ЊC. Before we conducted PCR, the concentration of the DNA was analyzed by photometer (optical density, 260 nm). The average of 3 determinations was used.
The touchdown-nested PCR was performed as described elsewhere by Tong and Sillis [27] and Mahony et al. [28] . The gene coding for the major outer membrane protein (ompA) was amplified. The outer pair of primers (CP-1, 5 -TTACAAG-CCTTGCCTGTAGG-3 ; CP-2, 5 -GCGATCCCAAATGTTTA-AGGC-3 ) were common to both the ompA gene of C. pneumoniae and Chlamydia psittaci, and the inner pair of primers (CPC, 5 -TTATTAATTGATGGTACAATA-3 ; CPD, 5 -ATCTA-CGGCAGTAGTATAGTT-3 ) were specific to a variable domain of the ompA gene of C. pneumoniae. The outer primers amplified a 333-bp fragment, whereas the inner primers amplified a 207-bp fragment. The amplification reaction was performed in a volume of 100 mL containing 0.8 mg of extracted DNA, 10 mmol/L Tris HCl (pH, 8.3), 50 mmol/L KCl, and a 200-mmol/ L concentration of 4 deoxynucleoside triphosphates. The ratio of a volume of template DNA to volume of reaction mix was determined as indicated by Mahony et al. [28] . Touchdownnested PCR conditions were as follows: the first round of amplification employed 1.5 mmol/L MgCl 2 , 0.4 mmol/L primers, and 2.5 U of AmpliTaq Gold DNA polymerase (Perkin-Elmer) and involved 20 cycles of 1 min at 94ЊC, 1 min at 65ЊC decreased by 0.5ЊC per cycle, and 1 min at 72ЊC, plus an additional 20 cycles of 1 min at 94ЊC, 1 min at 55ЊC, and 1 min at 72ЊC. The PCR products amplified by outer primers (CP-1-CP-2) were filtered by a microcon-PCR (Millipore), and a volume of 10 mL was added to a new 100-mL PCR mixture for a second amplification. The second round of amplification employed 3 mmol/L MgCl 2 , 1 mmol/L primers, and 2.5 U of AmpliTaq Gold DNA polymerase and involved 30 cycles of 1 min at 94ЊC, 1 min at 50ЊC, and 1 min at 72ЊC. The amplification products Table 2 .
Characteristics of subjects in a study of temporal changes in the prevalence of Chlamydia pneumoniae DNA in PBMCs. were visualized in 2% agarose with ethidium bromide staining by standard techniques. Purified C. pneumoniae DNA from strain YK-41 was used as a positive control. The lower detection limit of the PCR was 0.1 inclusion-forming units. PCR was also performed with primers for a b-globin gene sequence to confirm that the total DNA quantity of each sample was similar and that no false-negative results were generated [13] .
To avoid the risk of contamination, all reactions were performed under stringent conditions. The DNA extraction, first PCR amplification, second PCR amplification, and electrophoresis were performed in separate rooms. Aerosol barrier pipette tips, dedicated laboratory coats, and gloves were also used. Four negative controls, consisting of sterile distilled water in place of the clinical specimen, were run along with every 5 samples for all reactions. Two sets of negative controls were incorporated at the DNA extraction stage, and additional negative controls were added during the first and second PCR steps. In addition, we examined the reproducibility and validity of our PCR method by repeated PCR tests and sequencing of positive PCR products, respectively. Data analysis. Data are expressed as or as a mean ‫ע‬ SD percentage. Categorical data were analyzed by Fisher's exact test or by the x 2 test with Yates' correction. Continuous variables were analyzed by the unpaired t test or by 1-way analysis of variance. A P value of !.05 was considered to be statistically significant.
RESULTS
The prevalence of C. pneumoniae DNA in PBMCs. Table 1 shows the characteristics of the study populations included in the first portion of the study. The frequency of persons with diabetes mellitus and of ex-smokers was significantly higher among patients with ACS and those with stable CAD than among control subjects. There was no significant difference in the prevalence of positive C. pneumoniae DNA in PBMCs when comparing the 3 groups (patients with ACS, 46 Temporal changes in the prevalence of C. pneumoniae DNA in PBMCs. Table 2 shows the characteristics of the study populations included in the second portion of the study. There was a significantly higher proportion of ex-smokers among patients with CAD patients than among control subjects (44.4% vs. 12.5%;
). As is illustrated in figure 1 , there was no P ! .01 significant difference in the prevalence of C. pneumoniaepositive DNA in PBMCs when comparing patients with CAD with control subjects in the different time periods (January through March, 16 . However, the prevalence of C. pneumoniae-positive DNA in PBMCs was more frequent in the first 3-month period (January through March) than in the other 3-month periods for both patients with CAD and control subjects ( ). The rate of C. pneu-P ! .05 moniae-positive DNA in PBMCs decreased after April, especially during September and October, but it increased after November (figure 2).
Of the 59 subjects, 8 (4 patients with CAD and 4 control subjects) had persistently negative PCR test results; 25 subjects (13 patients with CAD and 12 control subjects) had 1 positive PCR test result, 20 subjects (7 patients with CAD and 13 control subjects) had 2 positive PCR test results, and 6 subjects (3 patients with CAD and 3 control subjects) had 3 positive PCR test results. No subjects had positive results of all 4 PCR tests. Finally, 51 subjects (86.4%) had у1 positive PCR test (table 3) .
Reproducibility and validity of the PCR method. To examine the reproducibility of our PCR method, each PCR test was repeated for the first 60 consecutive samples, and the results were compared. In the first run, 26 samples yielded positive results, and 34 samples yielded negative results. In the second run, 25 samples yielded positive results, and 35 samples yielded negative results. This represented a positive concordance in 59 (98.3%) of 60 samples. To examine the validity of our PCR method, the 26 samples that had positive results in the first run were sequenced, and all were consistent with the target sequence in C. pneumoniae DNA.
DISCUSSION
The relationship between C. pneumoniae DNA in PBMCs and CAD. Table 4 shows the relationship between C. pneumoniae DNA in PBMCs and CAD. The report by Boman et al. [13] was the first to suggest a relationship between C. pneumoniae DNA in PBMCs and CAD. However, Boman et al. [13] demonstrated no significant difference in the prevalence of C. pneumoniae DNA in PBMCs when comparing patients with CAD and middle-aged blood donors (59.4% vs. 46.1%). In contrast, Wong et al. [14] reported that the prevalence of C. pneumoniae DNA in PBMCs was significantly higher in men with angiographically confirmed CAD than in those with normal coronaries (8.8% vs. 2.9%) and concluded that the presence of circulating C. pneumoniae DNA was a stronger predictor of CAD than were any of the known risk factors, such as smoking, hypercholesterolemia, hypertension, diabetes mellitus, and family history of CAD (OR, 3.2; 95% CI, 1.2-8.9). Sessa et al. [16] recently reported that the prevalence of C. pneumoniae DNA in PBMCs was significantly higher in patients with ACS than in healthy subjects (25.8% vs. 4.8%).
In the present study, there were no significant differences in the prevalence of C. pneumoniae DNA in PBMCs when comparing patients with ACS, those with stable CAD, and control subjects. There are several possible explanations for the discrepancies among the published studies, including the present study. First, each study involved unique patient populations that may have differences in the relationship between C. pneumoniae DNA in PBMCs and CAD. Second, the present study demonstrated seasonal variability in the prevalence of C. pneumoniae DNA in PBMCs. Thus, potential intergroup variability in the time that blood samples were obtained may lead to intergroup differences in the prevalence of C. pneumoniae DNA in PBMCs. In the present study, there were no significant differences in the prevalence of C. pneumoniae DNA in PBMCs in any 3-month period when comparing 27 patients with CAD and 32 control subjects. Thus, circulating C. pneumoniae DNA is unlikely to be a useful indicator of CAD or ACS.
Seasonal variability in the prevalence of C. pneumoniae DNA in PBMCs. Table 5 shows the seasonal change in the prevalence of C. pneumoniae DNA in PBMCs. Intermonth differences in the prevalence of C. pneumoniae DNA in PBMCs have been suggested by previous studies [17, [29] [30] [31] . Smieja et al. [17, 29] found a higher prevalence of C. pneumoniae DNA in winter and spring than in other seasons. Rassu et al. [30] In the present study, the prevalence of C. pneumoniae-positive DNA in PBMCs was significantly higher during the first 3-month period (January through March) than during other 3-month periods. Furthermore, the rate of C. pneumoniae-positive DNA in PBMCs decreased after April, especially in September and October, but it increased after November. These data suggest that the prevalence of C. pneumoniae DNA in PBMCs has a seasonal variability and are consistent with the previous studies [17, 29, 30] . Further studies are required to clarify whether this seasonal variability is due to a seasonal occurrence of acute C. pneumoniae infections in the community and whether this seasonality is a worldwide phenomenon. Significance of C. pneumoniae DNA in PBMCs. Although the present study indicates that circulating C. pneumoniae DNA is unlikely to be a useful indicator of CAD or ACS, it does not disprove the hypothesis that C. pneumoniae may contribute to the development of atherosclerotic diseases. C. pneumoniae infection may contribute to the development of atherosclerosis by modulating macrophage-lipoprotein interaction and inducing the expression of various cytokines [32, 33] , adhesion molecules [34] [35] [36] [37] [38] , and chemokines [34] [35] [36] [37] [38] in atheroma-associated cells. Furthermore, C. pneumoniae infection may produce procoagulants [39, 40] and trigger antibody-mediated endo-thelial cytotoxicity through an immunological cross-reaction [40, 41] . Given the results of our serial PCR tests that circulating C. pneumoniae DNA was commonly detected during wintertime and early spring and that the majority (86.4%) of subjects had у1 positive PCR test result, the Japanese population appears to have ample opportunity to acquire vascular C. pneumoniae infection that may contribute to the development of atherosclerosis.
Limitations of the present study. The present study has several limitations. First, 38 (43.2%) of 88 control subjects did not undergo coronary arteriography and may have had significant but asymptomatic coronary artery stenosis. Second, the detection of C. pneumoniae DNA by PCR is not definitive proof of the actual presence of C. pneumoniae organisms. However, DNA from dead C. pneumoniae in tissue specimens is rapidly degraded in vivo [12] , and the detection of C. pneumoniae in PBMCs by PCR is reproducible and correlates with other detection techniques, such as immunoelectron microscopy and culture [42] . Third, the origin of C. pneumoniae DNA in PBMCs remains unclear. Because our subjects had no symptoms of respiratory tract infection within 4 weeks of the obtainment of blood samples, a plausible origin may be systemic dissemination of C. pneumoniae after latent acute C. pneumoniae infection. Indeed, asymptomatic infections of C. pneumoniae might be common [43, 44] . Alternatively, systemic release of C. pneumoniae organisms may result from chronic infections in the lung and pharynx [45] [46] [47] . Fourth, the prevalence of C. pneumoniae DNA in PBMCs in our study was higher than in other reports [16, 17] . Although an outbreak of C. pneumoniae infection during the study could have led to the high prevalence of C. pneumoniae in PBMCs, there was no evidence of any outbreak in our area during the study. The more likely explanation is that the first samples were obtained in the wintertime and early spring, when seasonal prevalence appears to be at its highest. The difference in the PCR methods used for the detection of C. pneumoniae in PBMCs can be also an important cause of the interstudy variability in the prevalence of C. pneumoniae DNA in PBMCs. Mahony et al. [28] recently showed that the ompA-nested PCR used in our study was more sensitive for the detection of C. pneumoniae DNA in PBMCs and had more reproducible results than did other PCR methods used in previous studies. Our PCR method met the criteria recommended by Dowell et al. [25] , and we confirmed the reproducibility and validity of our PCR method. Therefore, we believe that the reliability of our results is high.
Conclusions. The prevalence of C. pneumoniae DNA in PBMCs in patients with ACS or stable CAD is comparable to that found in control subjects in the Japanese adult population. The presence of C. pneumoniae DNA in PBMCs is unlikely to be an indicator of ACS or CAD. Rather, it appears to be a seasonal phenomenon, with higher a prevalence during wintertime and early spring in Japanese adults.
